세계의 안과용 의약품 시장 : 예측(2025-2030년)

The Global Ophthalmic Drugs Market is expected to grow from USD 33.495 billion in 2025 to USD 47.031 billion in 2030, at a CAGR of 7.02%.

The Global Ophthalmic Drugs Market Study provides a comprehensive analysis of the evolving ophthalmic drugs industry, tailored for industry experts seeking actionable insights into market dynamics, technological advancements, and competitive strategies. This study examines key market segments, including indications, product types, drug forms, drug classes, delivery methods, distribution channels, and geographical regions, offering a detailed perspective on growth opportunities and challenges.

Study Overview

The Global Ophthalmic Drugs Market Study is structured to deliver a granular understanding of the market landscape. It covers critical aspects such as market drivers, restraints, opportunities, and technological trends shaping the industry. The study also includes a robust competitive analysis, highlighting strategic developments from key players to equip stakeholders with the insights needed to navigate this dynamic market. The analysis spans regions, including North America, South America, Europe, Middle East and Africa, and Asia Pacific, ensuring a global perspective.

Competitive Environment and Analysis

In the Global Ophthalmic Drugs Market Study, the competitive environment is a focal point, offering an in-depth look at major players and their strategic initiatives. Key developments from leading companies underscore the dynamic nature of the market:

• Novartis AG: Novartis has strengthened its position through advancements in retinal disorder treatments, notably with its anti-VEGF therapy, Beovu (brolucizumab). The company has focused on expanding clinical trials to address unmet needs in wet age-related macular degeneration (AMD), positioning itself as a leader in the retinal problems segment. Its strategic partnerships with research institutions aim to accelerate innovation in intraocular delivery methods, enhancing treatment efficacy.
• Alcon Inc. (Ivantis): Alcon has made significant strides in glaucoma management with its Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device. This development reflects Alcon's commitment to integrating drug-device combination therapies, addressing the growing demand for innovative delivery methods like subconjunctival administration. The company's acquisition of Ivantis has bolstered its portfolio, enhancing its competitive edge in the glaucoma indication segment.

These developments highlight how key players are leveraging innovation and strategic collaborations to capture market share and address evolving patient needs in the Global Ophthalmic Drugs Market Study.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

By Indication

• Dry Eye
• Glaucoma
• Infection/Inflammation/Allergies
• Retinal Problems
• Others

By Product type

• OTC Drug
• Prescription Drug

By Drug Form

• Liquid
• Semi-solid
• Solid

By Drug Class

• Anti-Inflammatory
• Anesthetic
• Anti-Allergy
• Others

By Delivery Method

• Topical (Eye Drops, Ointments)
• Intraocular
• Intravitreal
• Subconjunctival
• Systemic
• Oral
• Intravenous

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• UK
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Taiwan
• Thailand
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL OPHTHALMIC DRUGS MARKET BY INDICATION

• 5.1. Introduction
• 5.2. Dry Eye
• 5.3. Glaucoma
• 5.4. Infection/Inflammation/Allergies
• 5.5. Retinal Problems
• 5.6. Others

6. GLOBAL OPHTHALMIC DRUGS MARKET BY PRODUCT TYPE

• 6.1. Introduction
• 6.2. OTC Drug
• 6.3. Prescription Drug

7. GLOBAL OPHTHALMIC DRUGS MARKET BY DRUG FORM

• 7.1. Introduction
• 7.2. Liquid
• 7.3. Semi-solid
• 7.4. Solid

8. GLOBAL OPHTHALMIC DRUGS MARKET BY DRUG CLASS

• 8.1. Introduction
• 8.2. Anti-Inflammatory
• 8.3. Anesthetic
• 8.4. Anti-Allergy
• 8.5. Others

9. GLOBAL OPHTHALMIC DRUGS MARKET BY DELIVERY METHOD

• 9.1. Introduction
• 9.2. Topical
• 9.3. Intraocular
  • 9.3.1. Intravitreal
  • 9.3.2. Subconjunctival
• 9.4. Systemic
  • 9.4.1. Oral
  • 9.4.2. Intravenous

10. GLOBAL OPHTHALMIC DRUGS MARKET BY DISTRIBUTION CHANNEL

• 10.1. Introduction
• 10.2. Hospital Pharmacies
• 10.3. Retail Pharmacies
• 10.4. Online Pharmacies

11. GLOBAL OPHTHALMIC DRUGS MARKET BY GEOGRAPHY

• 11.1. Introduction
• 11.2. North America
  • 11.2.1. By Indication
  • 11.2.2. By Product Type
  • 11.2.3. By Drug Form
  • 11.2.4. By Drug Class
  • 11.2.5. By Delivery Method
  • 11.2.6. By Distribution Channel
  • 11.2.7. By Country
    • 11.2.7.1. USA
    • 11.2.7.2. CanadaHybrid in
    • 11.2.7.3. Mexico
• 11.3. South America
  • 11.3.1. By Indication
  • 11.3.2. By Product Type
  • 11.3.3. By Drug Form
  • 11.3.4. By Drug Class
  • 11.3.5. By Delivery Method
  • 11.3.6. By Distribution Channel
  • 11.3.7. By Country
    • 11.3.7.1. Brazil
    • 11.3.7.2. Argentina
    • 11.3.7.3. Others
• 11.4. Europe
  • 11.4.1. By Indication
  • 11.4.2. By Product Type
  • 11.4.3. By Drug Form
  • 11.4.4. By Drug Class
  • 11.4.5. By Delivery Method
  • 11.4.6. By Distribution Channel
  • 11.4.7. By Country
    • 11.4.7.1. United Kingdom
    • 11.4.7.2. Germany
    • 11.4.7.3. France
    • 11.4.7.4. Spain
    • 11.4.7.5. Others
• 11.5. Middle East and Africa
  • 11.5.1. By Indication
  • 11.5.2. By Product Type
  • 11.5.3. By Drug Form
  • 11.5.4. By Drug Class
  • 11.5.5. By Delivery Method
  • 11.5.6. By Distribution Channel
  • 11.5.7. By Country
    • 11.5.7.1. Saudi Arabia
    • 11.5.7.2. UAE
    • 11.5.7.3. Others
• 11.6. Asia Pacific
  • 11.6.1. By Indication
  • 11.6.2. By Product Type
  • 11.6.3. By Drug Form
  • 11.6.4. By Drug Class
  • 11.6.5. By Delivery Method
  • 11.6.6. By Distribution Channel
  • 11.6.7. By Country
    • 11.6.7.1. China
    • 11.6.7.2. Japan
    • 11.6.7.3. India
    • 11.6.7.4. South Korea
    • 11.6.7.5. Taiwan
    • 11.6.7.6. Others

12. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 12.1. Major Players and Strategy Analysis
• 12.2. Market Share Analysis
• 12.3. Mergers, Acquisitions, Agreements, and Collaborations
• 12.4. Competitive Dashboard

13. COMPANY PROFILES

• 13.1. Sun Pharmaceutical Industries, Inc.
• 13.2. AbbVie
• 13.3. Alcon Inc. (Ivantis)
• 13.4. Mundipharma International
• 13.5. F. Hoffmann-La Roche Ltd
• 13.6. Novartis AG
• 13.7. Sentiss Pharma Pvt. Ltd.
• 13.8. Santen Pharmaceutical Co., Ltd
• 13.9. Bausch & Lomb
• 13.10. Bayer AG
• 13.11. Aerie Pharmaceuticals, Inc

14. APPENDIX

• 14.1. Currency
• 14.2. Assumptions
• 14.3. Base and Forecast Years Timeline
• 14.4. Key benefits for the stakeholders
• 14.5. Research Methodology
• 14.6. Abbreviations